open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-05-22
Get Citation

Simultaneous Integrated Boost Radiotherapy in Unresectable Stage IV (M0) Head and Neck Squamous Cell Cancer Patients: Daily Clinical Practice

Giuseppe Iatì, Silvana Parisi, Anna Santacaterina, Antonio Pontoriero, Alberto Cacciola, Anna Brogna, Angelo Platania, Carmela Palazzolo, Domenico Cambareri, Valerio Davì, Ilenia Napoli, Sara Lillo, Cesare Severo, Consuelo Tamburella, Roberta Vadalà, Pietro Delia, Stefano Pergolizzi
DOI: 10.1016/j.rpor.2020.04.006
·
Rep Pract Oncol Radiother 2020;25(3):399-404.

open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-05-22

Abstract

Aim

To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice.

Background

Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies.

Material and Methods

We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated.

Results

37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months.

Conclusion

SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.

Abstract

Aim

To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice.

Background

Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies.

Material and Methods

We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated.

Results

37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months.

Conclusion

SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.

Get Citation

Keywords

Intensity-Modulated radiotherapy (IMRT); Simultaneous integrated boost (SIB); Head and neck cancer; Radiotherapy; Systemic therapies

About this article
Title

Simultaneous Integrated Boost Radiotherapy in Unresectable Stage IV (M0) Head and Neck Squamous Cell Cancer Patients: Daily Clinical Practice

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 3 (2020)

Pages

399-404

Published online

2020-05-01

DOI

10.1016/j.rpor.2020.04.006

Bibliographic record

Rep Pract Oncol Radiother 2020;25(3):399-404.

Keywords

Intensity-Modulated radiotherapy (IMRT)
Simultaneous integrated boost (SIB)
Head and neck cancer
Radiotherapy
Systemic therapies

Authors

Giuseppe Iatì
Silvana Parisi
Anna Santacaterina
Antonio Pontoriero
Alberto Cacciola
Anna Brogna
Angelo Platania
Carmela Palazzolo
Domenico Cambareri
Valerio Davì
Ilenia Napoli
Sara Lillo
Cesare Severo
Consuelo Tamburella
Roberta Vadalà
Pietro Delia
Stefano Pergolizzi

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl